- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Telomir to Buy TELI | 2 | Baystreet.ca | ||
| Di | Telomir Pharmaceuticals executes LOI for worldwide rights to Telomir-1 | 3 | Seeking Alpha | ||
| Di | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth | 180 | ACCESS Newswire | Unifying global IP rights and enabling up to $5 million in potential shareholder contributions, the agreement strengthens Telomir's foundation for partnerships, licensing, and long-term value creation.... ► Artikel lesen | |
| 14.10. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer | 148 | ACCESS Newswire | Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1's consistent impact on cancer cell survival pathways. MIAMI... ► Artikel lesen | |
| 14.10. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| TELOMIR PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 09.10. | Telomir Pharmaceuticals Touts Promising Action From Its Lead Breast Cancer Drug | 1 | Benzinga.com | ||
| 09.10. | Telomir stock soars after drug shows promise against aggressive breast cancer | 3 | Investing.com | ||
| 09.10. | Telomir-1 shows promise against triple-negative breast cancer | 4 | Investing.com | ||
| 09.10. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells | 202 | ACCESS Newswire | New findings show Telomir-1 shuts down cellular energy pathways and mitochondrial function in aggressive breast cancer cells, leading to cell death through iron-dependent regulation. MIAMI, FL / ACCESS... ► Artikel lesen | |
| 07.10. | Telomir stock soars after tumor suppressor gene reactivation results | 4 | Investing.com | ||
| 07.10. | Telomir-1 shows promise in reactivating tumor suppressor genes | 2 | Investing.com | ||
| 07.10. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasi | 196 | ACCESS Newswire | Findings show that Telomir-1 restores the body's natural tumor suppressor defenses by reversing abnormal DNA methylation of MASPIN and RASSF1A - genes that help block invasion, limit metastasis, and... ► Artikel lesen | |
| 07.10. | McCormick, Telomir Pharmaceuticals And 3 Stocks To Watch Heading Into Tuesday | 5 | Benzinga.com | ||
| 06.10. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 18.09. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies | 213 | ACCESS Newswire | New in vitro results show Telomir-1 adds KDM5 family inhibition to its previously reported KDM2/KDM6 and DNA methylation activity, potentially representing a novel frontier in epigenetic therapy where... ► Artikel lesen | |
| 18.09. | Telomir Pharmaceuticals: Neue In-vitro-Daten belegen epigenetische Aktivität von Telomir-1 | 3 | Investing.com Deutsch | ||
| 18.09. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.09. | Telomir's drug candidate shows promise in reversing cancer gene silencing | 2 | Investing.com | ||
| 09.09. | Telomir: Wirkstoffkandidat könnte Gen-Stummschaltung bei Krebs umkehren | 4 | Investing.com Deutsch | ||
| 09.09. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy | 282 | ACCESS Newswire | New preclinical findings highlight Telomir-1's ability to reverse CDKN2A gene silencing by DNA methylation, reactivating this gene - often called the body's natural "cell cycle brake." These results... ► Artikel lesen |
1 2 3 4 Weiter >>
77 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 92,45 | +0,22 % | Diese Biotech-Aktie könnte Big Pharma das Fürchten lehren - mit einem oralen Abnehm-Blockbuster und Milliardenpotenzial bei MS! | Anzeige / WerbungWährend die Aktien von BioNTech und Evotec auf der Stelle treten, befindet sich BioNxt Solutions im Aufwärtstrend. Denn das Unternehmen mischt gerade Big Pharma auf. Die Ankündigung... ► Artikel lesen | |
| MODERNA | 23,745 | +0,25 % | Wer im Kampf gegen Krebs auf jeden Fall verdient: NetraMark, Moderna, BioNTech | Zwei Biotech-Pioniere, Moderna und BioNTech, stehen nach ihrem COVID-19-Impfstoff-Erfolg erneut im Rampenlicht - diesmal in einem Wettrennen um innovative Krebstherapien. Beide Unternehmen setzen auf... ► Artikel lesen | |
| VALNEVA | 4,146 | -0,34 % | Valneva-Aktie im Mittelpunkt des Geschehens - Insider erwarten Bewegung! | ||
| CRISPR THERAPEUTICS | 62,00 | -0,80 % | CRISPR THERAPEUTICS AG verharrt - jetzt wird's brenzlig! | ||
| INOVIO PHARMACEUTICALS | 2,080 | +4,00 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| OCUGEN | 1,333 | -1,19 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,350 | -0,23 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity | Study to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735
Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens to be Evaluated... ► Artikel lesen | |
| BAVARIAN NORDIC | 31,940 | -0,37 % | Bavarian Nordic: Höheres Übernahme-Angebot mit Ansage! | Der Übernahmeprozess um den europäischen Impfstoff-Entwickler Bavarian Nordic geht in die nächste Runde. Wie vom AKTIONÄR antizipiert, muss das bietende Investorenduo bestehend aus Permira und Nordic... ► Artikel lesen | |
| GERON | 1,120 | +1,96 % | GERON CORP - 8-K, Current Report | ||
| IMMUNITYBIO | 2,075 | -1,14 % | ImmunityBio: Zwischen Hype und Hoffnung | Die Aktie von ImmunityBio hat in den vergangenen eineinhalb Jahren deutlich an Wert verloren, nachdem Finanzierungsbedarf zu einer erheblichen Verwässerung führte. Dennoch rückt das Unternehmen dank... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 1,966 | +0,71 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | ||
| ZAI LAB LTD ADR | 24,600 | -2,38 % | ZAI LAB (09688): OVERSEAS REGULATORY ANNOUNCEMENT - FORM 8-K | ||
| VERASTEM | 6,800 | -1,45 % | Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma | GFH375 resulted in a 41% ORR for patients with heavily pre-treated pancreatic ductal adenocarcinoma (68% had received 2 or more prior lines of therapy) at the 600 mg daily dose At month four... ► Artikel lesen | |
| APELLIS PHARMACEUTICALS | 22,190 | +8,88 % | Apellis Pharmaceuticals, Inc.: New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week | Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission (UPCR =0.5 g/g) achieved in one-third of... ► Artikel lesen | |
| GRAIL | 71,80 | -0,55 % | Grail war NASDAQ-Tagessieger | Der kalifornische Krebstest-Entwickler hat die vor zwei Wochen gefahrene Attacke des Shortsellers Ningi Research zunächst offenbar abgeschüttelt. Der Leerverkäufer hatte Zweifel am späteren Erfolge... ► Artikel lesen |
TELOMIR PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,510 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELOMIR PHARMACEUTICALS INC finden Sie auf Wallstreet Online.